Insiders: The top 20 rare disease specialists spotlight key biotech trends behind the boom

Image: Biogen CEO Michel Vounatsos at the company's offices in Cambridge, MA on Jan. 3, 2017. The Boston Globe via Getty

Some of the most interesting ongoing discussions in biotech are focused on a few key points: how do you create value, which companies are creating the greatest value and where is the next Biogen or Celgene coming from?

This piece is for all of you who care to know more about that.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->